BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Corbus Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Corbus Pharmaceuticals's drugs ru
 n\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06265727-10784@assetmemo.bio
DTSTAMP:20261121T005441Z
DTSTART;VALUE=DATE:20270116
DTEND;VALUE=DATE:20270117
SUMMARY:Sutantatug envedotin: Phase 1/2 readout est. (NCT06265727)
DESCRIPTION:Sutantatug envedotin\, phase 1/2.\nStudy: A Phase 1/2 Study to 
 Investigate CRB-701 in Solid Tumors\nEstimated primary completion: 16 Janu
 ary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sutantatug-
 envedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06265727
URL:https://assetmemo.bio/drug/sutantatug-envedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07768189-10784@assetmemo.bio
DTSTAMP:20261121T005441Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sutantatug envedotin: Phase 3 readout est. (NCT07768189)
DESCRIPTION:Sutantatug envedotin\, phase 3.\nStudy: A Study to Evaluate CRB
 -701 Compared to Investigator's Choice Therapy in Previously Treated Oroph
 aryngeal Squamous Cell Carcinoma\nEstimated primary completion: December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/sutantatug-enved
 otin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07768189
URL:https://assetmemo.bio/drug/sutantatug-envedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06989671-10784@assetmemo.bio
DTSTAMP:20261121T005441Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Sutantatug envedotin: Phase 2 readout est. (NCT06989671)
DESCRIPTION:Sutantatug envedotin\, phase 2.\nStudy: SYS6002 Plus JMT101 and
  Enlonstobart Injection in Participants With HNSCC\nEstimated primary comp
 letion: 30 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/sutantatug-envedotin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06989671
URL:https://assetmemo.bio/drug/sutantatug-envedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230626-10784@assetmemo.bio
DTSTAMP:20261121T005441Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Sutantatug envedotin: Phase 3 readout est. (NCT07230626)
DESCRIPTION:Sutantatug envedotin\, phase 3\, Cervical Cancer.\nStudy: SYS60
 02 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer\nEstimated p
 rimary completion: 1 January 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/sutantatug-envedotin#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07230626
URL:https://assetmemo.bio/drug/sutantatug-envedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07374549-10784@assetmemo.bio
DTSTAMP:20261121T005441Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Sutantatug envedotin: Phase 2 readout est. (NCT07374549)
DESCRIPTION:Sutantatug envedotin\, phase 2\, Urothelial Carcinoma.\nStudy: 
 SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma\nEstimate
 d primary completion: 1 June 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/sutantatug-envedotin#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07374549
URL:https://assetmemo.bio/drug/sutantatug-envedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07526792-10784@assetmemo.bio
DTSTAMP:20261121T005441Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Sutantatug envedotin: Phase 3 readout est. (NCT07526792)
DESCRIPTION:Sutantatug envedotin\, phase 3\, Urothelial Carcinoma.\nStudy: 
 SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Ur
 othelial Carcinoma\nEstimated primary completion: 1 June 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/sutantatug-envedotin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07526792
URL:https://assetmemo.bio/drug/sutantatug-envedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
